Literature DB >> 14695145

Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers.

Wen G Jiang1, Gareth Watkins, Jane Lane, Giles H Cunnick, Anthony Douglas-Jones, Kefah Mokbel, Robert E Mansel.   

Abstract

PURPOSE: Rho family members are small GTPases that are known to regulate malignant transformation and motility of cancer cells. The activities of Rhos are regulated by molecules such as guanine nucleotide dissociation inhibitors (GDIs). This study determined the levels of expression and the distribution of Rho-A, -B, -C, and -G, and Rho-6, -7, and -8, as well as Rho-GDI-beta, and Rho-GDI-gamma, in breast cancer and assessed their prognostic value. EXPERIMENTAL
DESIGN: The distribution and location of Rhos and RhoGDIs were assessed using immunohistochemical staining of frozen sections. The levels of transcripts of these molecules were determined using a real-time quantitative PCR. Levels of expression were analyzed against nodal involvement and distant metastasis, grade, and survival over a 6-year follow-up period.
RESULTS: The levels of Rho-C, Rho-6, and Rho-G were significantly higher in breast cancer tissues (n = 120) than in background normal tissues (n = 32). However, the level of Rho-A and -B and rho-7 and -8 was found to be similar in tumor and normal tissues. Immunohistochemical staining revealed the high level of staining of Rho-C protein in tumor cells. The levels of Rho-GDI-gamma transcripts were found to be significantly lower in tumor tissues than in normal tissues (P < 0.05 and P < 0.001, respectively). Node-positive tumors have significantly higher levels of Rho-C and Rho-G, and lower levels of Rho-GDI and Rho-GDI-gamma transcripts, than do node-negative tumors. Significantly higher levels of Rho-C and Rho-G were seen in patients who died of breast cancer than in those who remained disease free. Patients with recurrent disease, with metastasis or who died of breast cancer, also exhibited higher levels of Rho-6 but lower levels of Rho-GDI-gamma. Higher-grade tumors were also associated with low levels of Rho-GDI and Rho-GDI-gamma.
CONCLUSIONS: Raised levels of Rho-C, Rho-G and Rho-6 and reduced expression of Rho-GDI and -GDI-gamma in breast tumor tissues are correlated with the nodal involvement and metastasis. This suggests that the expression of Rhos and Rho-GDIs in breast cancer is unbalanced and that this disturbance has clinical significance in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14695145

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  68 in total

1.  RhoGDI2 antagonizes ovarian carcinoma growth, invasion and metastasis.

Authors:  Ellen V Stevens; Natalie Banet; Cercina Onesto; Ana Plachco; Jamie K Alan; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Pei Fen Kuan; Jinsong Liu; C Ryan Miller; Dominico Vigil; Lee M Graves; Channing J Der
Journal:  Small GTPases       Date:  2011-07-01

2.  Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA.

Authors:  Jie Ding; Shenglin Huang; Shunquan Wu; Yingjun Zhao; Linhui Liang; Mingxia Yan; Chao Ge; Jian Yao; Taoyang Chen; Dafang Wan; Hongyang Wang; Jianren Gu; Ming Yao; Jinjun Li; Hong Tu; Xianghuo He
Journal:  Nat Cell Biol       Date:  2010-03-21       Impact factor: 28.824

3.  RhoGDIbeta lacking the N-terminal regulatory domain suppresses metastasis by promoting anoikis in v-src-transformed cells.

Authors:  Takahide Ota; Masayo Maeda; Shiho Sakita-Suto; Xinwen Zhou; Manabu Murakami; Tsutomu Takegami; Masaaki Tatsuka
Journal:  Clin Exp Metastasis       Date:  2006-11-17       Impact factor: 5.150

4.  Phosphorylation of RhoGDI by Src regulates Rho GTPase binding and cytosol-membrane cycling.

Authors:  Céline DerMardirossian; Gabriel Rocklin; Ji-Yeon Seo; Gary M Bokoch
Journal:  Mol Biol Cell       Date:  2006-08-30       Impact factor: 4.138

5.  KiSS-1 expression in human breast cancer.

Authors:  Tracey A Martin; Gareth Watkins; Wen G Jiang
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

6.  Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression.

Authors:  Chul-Kee Park; Jin Hyun Kim; Min Jeong Moon; Ji Hye Jung; Su-Young Lim; Sung-Hye Park; Jong-Hoon Kim; Dong Gyu Kim; Hee-Won Jung; Byung-Kyu Cho; Sun Ha Paek
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-26       Impact factor: 4.553

Review 7.  Rho GTPases: functions and association with cancer.

Authors:  Saskia I J Ellenbroek; John G Collard
Journal:  Clin Exp Metastasis       Date:  2007-11-14       Impact factor: 5.150

8.  Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signaling.

Authors:  Yaqin Zhang; Leslie A Rivera Rosado; Sun Young Moon; Baolin Zhang
Journal:  J Biol Chem       Date:  2009-03-06       Impact factor: 5.157

9.  N-WASP is a putative tumour suppressor in breast cancer cells, in vitro and in vivo, and is associated with clinical outcome in patients with breast cancer.

Authors:  Tracey A Martin; Gordon Pereira; Gareth Watkins; Robert E Mansel; Wen G Jiang
Journal:  Clin Exp Metastasis       Date:  2007-11-06       Impact factor: 5.150

10.  Pituitary tumor-transforming 1 increases cell motility and promotes lymph node metastasis in esophageal squamous cell carcinoma.

Authors:  Tetsuo Ito; Yutaka Shimada; Takatsugu Kan; Stefan David; Yulan Cheng; Yuriko Mori; Rachana Agarwal; Bogdan Paun; Zhe Jin; Alexandru Olaru; James P Hamilton; Jian Yang; John M Abraham; Stephen J Meltzer; Fumiaki Sato
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.